Co-Diagnostics (CODX) Price & Analysis

Compare

1,565 Followers

CODX Stock Chart & Stats

Day’s Range― - ―

52-Week Range$0.23 - $1.40

Previous CloseN/A

Volume146.43K

Average Volume (3M)3.78M

Market Cap

$11.90M

Enterprise Value-$2.38M

Total Cash (Recent Filing)$13.36M

Total Debt (Recent Filing)$1.70M

Price to Earnings (P/E)―

Beta1.57

Next Earnings

Nov 06, 2025

EPS Estimate

-0.16

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.23

Shares Outstanding38,523,582

10 Day Avg. Volume643,651

30 Day Avg. Volume3,783,264

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap-0.20

Enterprise Value/Revenue-2.37

Enterprise Value/Gross Profit-5.99

Enterprise Value/Ebitda0.07

Forecast

1Y Price Target

$0.50

Price Target Upside61.29% Upside

Rating ConsensusHold

Number of Analyst Covering1

Bulls Say, Bears Say

Bulls Say

EarningsNet loss was $7.7M, or ($0.23) per share, less than the estimated loss of $8.3M.

Manufacturing ExpansionA new manufacturing facility has been inaugurated in South Salt Lake to manufacture components for the new Co-Dx PCR platform.

Operational EfficiencyProduction work flows are streamlined, efficiently staffed and ready for expansion in the company's new manufacturing facility in South Salt Lake.

Bears Say

Capital RequirementsCash flows from operating activities were ($8.3M) during 2Q25, indicating the need to raise additional capital in the near term to fund operations.

Regulatory ChallengesThe company withdrew its 510(k) application submitted to the FDA for its Co-Dx PCR COVID-19 test.

Revenue DeclineRevenue for the full year 2024 was $3.9M, representing a 43% year-over-year decline.

Co-Diagnostics News

Co-Diagnostics Earnings Call: Progress Amid Financial Struggles

Co-Diagnostics (($CODX)) has held its Q2 earnings call. Read on for the main highlights of the call. The...

6d ago

CODX

Co-Diagnostics Faces Financial Challenges and Regulatory Hurdles Amidst Hold Rating

H.C. Wainwright analyst Yi Chen has reiterated their neutral stance on CODX stock, giving a Hold rating today....

18d ago

CODX

Co-Diagnostics Reports Q2 2025 Financial Results

Co-Diagnostics ( ($CODX) ) has released its Q2 earnings. Here is a breakdown of the information Co-Diagnostics presented...

22d ago

CODX

Is CODX a Buy, Before Earnings?

Co-Diagnostics (CODX) is scheduled to report 2nd quarter earnings on 08/14/2025, after the market closes. Regarding Q2 estimates,...

25d ago

CODX

Co-Diagnostics Granted NASDAQ Grace Period Extension

Co-Diagnostics ( ($CODX) ) has issued an announcement. On July 10, 2025, Co-Diagnostics, Inc. received a notification from...

2M ago

CODX

Co-Diagnostics Holds Annual Shareholders Meeting

Co-Diagnostics ( ($CODX) ) has provided an update. On May 28, 2025, Co-Diagnostics, Inc. held its annual shareholders...

3M ago

CODX

Cautious Hold Rating for Co-Diagnostics Amid Financial Losses and Regulatory Uncertainties

Analyst Yi Chen from H.C. Wainwright reiterated a Hold rating on Co-Diagnostics (CODX – Research Report) and keeping...

4M ago

CODX

Co-Diagnostics Earnings Call: Progress Amid Financial Challenges

Co-Diagnostics (($CODX)) has held its Q1 earnings call. Read on for the main highlights of the call. Co-Diagnostics’...

4M ago

CODX

Co-Diagnostics Reports Q1 2025 Financial Results

Co-Diagnostics ( ($CODX) ) has released its Q1 earnings. Here is a breakdown of the information Co-Diagnostics presented...

4M ago

CODX

Co-Diagnostics Earnings Call: Progress Amid Challenges

Co-Diagnostics (($CODX)) has held its Q4 earnings call. Read on for the main highlights of the call. The...

5M ago

CODX

Co-Diagnostics price target lowered to $1 from $1.50 at H.C. Wainwright

H.C. Wainwright lowered the firm’s price target on Co-Diagnostics (CODX) to $1 from $1.50 and keeps a Neutral...

5M ago

CODX

Co-Diagnostics wins dismissal of class action lawsuit

Co-Diagnostics (CODX) announced that on March 4, the Securities & Governance Litigation Team at BakerHostetler, the legal firm...

6M ago

CODX

Co-Diagnostics withdraws 510k application to FDA for Co-Dx PCR COVID-19 Test

Co-Diagnostics (CODX) announced that, following a collaborative and informative dialogue with the Food and Drug Administration, the company...

7M ago

CODX

Co-Diagnostics completes updated clade Ib analysis of 2-Gene Mpox RUO test

Co-Diagnostics has performed an in silico analysis of the Co-Dx Logix Smart Mpox RUO test to evaluate the...

1y ago

CODX

CODX FAQ

What was Co-Diagnostics Inc’s price range in the past 12 months?

Co-Diagnostics Inc lowest stock price was $0.23 and its highest was $1.40 in the past 12 months.

What is Co-Diagnostics Inc’s market cap?

Co-Diagnostics Inc’s market cap is $11.90M.

When is Co-Diagnostics Inc’s upcoming earnings report date?

Co-Diagnostics Inc’s upcoming earnings report date is Nov 06, 2025 which is in 61 days.

How were Co-Diagnostics Inc’s earnings last quarter?

Co-Diagnostics Inc released its earnings results on Aug 14, 2025. The company reported -$0.23 earnings per share for the quarter, beating the consensus estimate of -$0.25 by $0.02.

Is Co-Diagnostics Inc overvalued?

According to Wall Street analysts Co-Diagnostics Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Co-Diagnostics Inc pay dividends?

Co-Diagnostics Inc does not currently pay dividends.

What is Co-Diagnostics Inc’s EPS estimate?

Co-Diagnostics Inc’s EPS estimate is -0.16.

How many shares outstanding does Co-Diagnostics Inc have?

Co-Diagnostics Inc has 38,523,582 shares outstanding.

What happened to Co-Diagnostics Inc’s price movement after its last earnings report?

Co-Diagnostics Inc reported an EPS of -$0.23 in its last earnings report, beating expectations of -$0.25. Following the earnings report the stock price went up 11.538%.

Which hedge fund is a major shareholder of Co-Diagnostics Inc?

Currently, no hedge funds are holding shares in CODX

Co-Diagnostics Stock Smart Score

Underperform

Fundamentals

Return on Equity

-63.40%

Trailing 12-Months

Asset Growth

-42.42%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Co-Diagnostics Inc

Co-Diagnostics, Inc. (CODX) is a molecular diagnostics company that develops and manufactures diagnostic tests based on its proprietary CoPrimer technology. The company focuses on the design of tests for infectious diseases, including COVID-19, and offers its products to laboratories, healthcare providers, and other organizations globally. Co-Diagnostics operates primarily in the healthcare sector, utilizing advanced technology to provide accurate and efficient diagnostic solutions.

Co-Diagnostics (CODX) Earnings & Revenues

Historic Earnings Reports

CODX Earnings Call

Q2 2025

0:00 / 0:00

Earnings Call Sentiment|Negative

The earnings call highlighted significant advancements in Co-Diagnostics' Co-DX PCR platform development, supported by major grants and upcoming clinical evaluations. However, these positives were overshadowed by a sharp revenue decline and increased losses, indicating financial challenges.View all CODX earnings summaries

CODX Stock 12 Month Forecast

Average Price Target

$0.50

▲(61.29% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"$2","-1":"-$1","-0.25":"-$0.25","0.5":"$0.5","1.25":"$1.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":0.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$0.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":0.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$0.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":0.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$0.50</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,-0.25,0.5,1.25,2],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2024","6":"Jan<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.25,0.2692307692307692,0.28846153846153844,0.3076923076923077,0.3269230769230769,0.34615384615384615,0.3653846153846154,0.38461538461538464,0.40384615384615385,0.4230769230769231,0.4423076923076923,0.46153846153846156,0.4807692307692308,{"y":0.5,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.25,0.2692307692307692,0.28846153846153844,0.3076923076923077,0.3269230769230769,0.34615384615384615,0.3653846153846154,0.38461538461538464,0.40384615384615385,0.4230769230769231,0.4423076923076923,0.46153846153846156,0.4807692307692308,{"y":0.5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.25,0.2692307692307692,0.28846153846153844,0.3076923076923077,0.3269230769230769,0.34615384615384615,0.3653846153846154,0.38461538461538464,0.40384615384615385,0.4230769230769231,0.4423076923076923,0.46153846153846156,0.4807692307692308,{"y":0.5,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1.16,"date":1709251200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.19,"date":1714521600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.05,"date":1717200000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.11,"date":1722470400000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.21,"date":1730419200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.94,"date":1733011200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.75,"date":1735689600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.5,"date":1740787200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.33,"date":1743465600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.36,"date":1746057600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.26,"date":1748736000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.28,"date":1751328000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.25,"date":1754006400000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >